bioMérieux Statistics
Total Valuation
bioMérieux has a market cap or net worth of 15.22 billion. The enterprise value is 15.27 billion.
| Market Cap | 15.22B |
| Enterprise Value | 15.27B |
Important Dates
The next estimated earnings date is Thursday, September 4, 2025.
| Earnings Date | Sep 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 43.65M |
Valuation Ratios
The trailing PE ratio is 34.00.
| PE Ratio | 34.00 |
| Forward PE | n/a |
| PS Ratio | 3.69 |
| PB Ratio | 3.49 |
| P/TBV Ratio | 4.93 |
| P/FCF Ratio | 45.71 |
| P/OCF Ratio | 22.02 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.68, with an EV/FCF ratio of 45.87.
| EV / Earnings | 34.12 |
| EV / Sales | 3.38 |
| EV / EBITDA | 13.68 |
| EV / EBIT | 21.06 |
| EV / FCF | 45.87 |
Financial Position
The company has a current ratio of 2.20, with a Debt / Equity ratio of 0.12.
| Current Ratio | 2.20 |
| Quick Ratio | 1.22 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.50 |
| Debt / FCF | 1.53 |
| Interest Coverage | 39.87 |
Financial Efficiency
Return on equity (ROE) is 10.68% and return on invested capital (ROIC) is 8.89%.
| Return on Equity (ROE) | 10.68% |
| Return on Assets (ROA) | 7.23% |
| Return on Invested Capital (ROIC) | 8.89% |
| Return on Capital Employed (ROCE) | 13.76% |
| Revenue Per Employee | 285,129 |
| Profits Per Employee | 30,964 |
| Employee Count | 14,754 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.81 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +25.48% in the last 52 weeks. The beta is 0.53, so bioMérieux's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | +25.48% |
| 50-Day Moving Average | 123.65 |
| 200-Day Moving Average | 113.61 |
| Relative Strength Index (RSI) | 65.93 |
| Average Volume (20 Days) | 8 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, bioMérieux had revenue of 4.12 billion and earned 447.46 million in profits. Earnings per share was 3.77.
| Revenue | 4.12B |
| Gross Profit | 2.29B |
| Operating Income | 660.42M |
| Pretax Income | 599.86M |
| Net Income | 447.46M |
| EBITDA | 981.68M |
| EBIT | 660.42M |
| Earnings Per Share (EPS) | 3.77 |
Balance Sheet
The company has 465.68 million in cash and 508.02 million in debt, giving a net cash position of -42.34 million.
| Cash & Cash Equivalents | 465.68M |
| Total Debt | 508.02M |
| Net Cash | -42.34M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 4.36B |
| Book Value Per Share | 36.92 |
| Working Capital | 1.41B |
Cash Flow
In the last 12 months, operating cash flow was 690.86 million and capital expenditures -358.01 million, giving a free cash flow of 332.85 million.
| Operating Cash Flow | 690.86M |
| Capital Expenditures | -358.01M |
| Free Cash Flow | 332.85M |
| FCF Per Share | n/a |
Margins
Gross margin is 55.66%, with operating and profit margins of 16.03% and 10.86%.
| Gross Margin | 55.66% |
| Operating Margin | 16.03% |
| Pretax Margin | 14.56% |
| Profit Margin | 10.86% |
| EBITDA Margin | 23.82% |
| EBIT Margin | 16.03% |
| FCF Margin | 8.08% |
Dividends & Yields
bioMérieux does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.06% |
| Shareholder Yield | 0.06% |
| Earnings Yield | 2.94% |
| FCF Yield | 2.19% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
bioMérieux has an Altman Z-Score of 5.99.
| Altman Z-Score | 5.99 |
| Piotroski F-Score | n/a |